6FYV

X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A

6FYV の概要

• エントリーDOI: 10.2210/pdb6fyv/pdb
• 関連するPDBエントリー: 6FYI 6FYK 6FYL 6FYO 6FYP 6FYR
• 分子名称: Dual specificity protein kinase CLK4, 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid, SULFATE ION, ... (4 entities in total)
• 機能のキーワード: splicing, kinase, phosphotransferase, transferase
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 40329.45

構造登録者

Kallen, J. (登録日: 2018-03-12, 公開日: 2018-07-18, 最終更新日: 2024-01-17)

主引用文献

Kallen, J.,Bergsdorf, C.,Arnaud, B.,Bernhard, M.,Brichet, M.,Cobos-Correa, A.,Elhajouji, A.,Freuler, F.,Galimberti, I.,Guibourdenche, C.,Haenni, S.,Holzinger, S.,Hunziker, J.,Izaac, A.,Kaufmann, M.,Leder, L.,Martus, H.J.,von Matt, P.,Polyakov, V.,Roethlisberger, P.,Roma, G.,Stiefl, N.,Uteng, M.,Lerchner, A.
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
ChemMedChem, 13:1997-2007, 2018

PubMed Abstract: CLK2 inhibition has been proposed as a potential mechanism to improve autism and neuronal functions in Phelan-McDermid syndrome (PMDS). Herein, the discovery of a very potent indazole CLK inhibitor series and the CLK2 X-ray structure of the most potent analogue are reported. This new indazole series was identified through a biochemical CLK2 Caliper assay screen with 30k compounds selected by an in silico approach. Novel high-resolution X-ray structures of all CLKs, including the first CLK4 X-ray structure, bound to known CLK2 inhibitor tool compounds (e.g., TG003, CX-4945), are also shown and yield insight into inhibitor selectivity in the CLK family. The efficacy of the new CLK2 inhibitors from the indazole series was demonstrated in the mouse brain slice assay, and potential safety concerns were investigated. Genotoxicity findings in the human lymphocyte micronucleus test (MNT) assay are shown by using two structurally different CLK inhibitors to reveal a major concern for pan-CLK inhibition in PMDS.

PubMed: 29985556
DOI: 10.1002/cmdc.201800344

実験手法

X-RAY DIFFRACTION (2.46 Å)